Pathological Complete Remission and Long-Term Outcome—What Do We Know in 2016?

The tale of HER2-positive breast cancer is a story of success. From the identification of HER2 protein overexpression as a strong predictor of poor outcome, to the introduction of the HER2-directed antibody trastuzumab in the metastatic setting, and to the neoadjuvant trastuzumab trials, major improvements in the outcome of patients with HER2-positive breast cancer have been achieved.

 The Lancet Oncology